When scientists at Cytokinetics Inc. have a question about contract research work they’re doing for a biotech startup, they don’t have far to go — just a few steps.
Biotech companies for years have taken on contract research projects, but the landlord-as-contractor arrangement between South San Francisco’s Cytokinetics and venture-backed Global Blood Targeting Inc. marks the latest model to bring money in the door while cutting costs.
For Global Blood, funded by Third Rock Ventures and working on a drug for sickle cell anemia, the move allows it to tap experienced researchers and reduce its startup costs. Publicly held Cytokinetics, meanwhile, keeps valued scientists busy and reduces its net cash burn, thanks to Global Blood payments for space and research work.
No comments:
Post a Comment